Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners Medicare Part D Step Therapy Covera…
    Ask Trek AI about this page
    CurrentHealthPartnersPolicy N/A

    2026 Medicare Part D Step Therapy Requirements

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines HealthPartners' Medicare Part D step therapy requirements effective May 1, 2026, specifying prior-use criteria for certain drugs on the Part D formulary. Affects Medicare Part D members and providers submitting pharmacy benefit claims under HealthPartners Part D.

    Policy Summary
    PayerHealthPartners
    Policy2026 Medicare Part D Step Therapy Requirements
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Last ReviewApr 21, 2026
    Next Review DateApril 21, 2026
    Key ActionDocument prior use of the specified comparator product within the previous 12 months to satisfy step therapy requirements for listed Step 2 drugs.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-05-01Effective date
    12 monthsLookback
    2Drug groups
    FID: 26132Formulary

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    RYTARY (carbidopa-levodopa ER) Initial Step Requirement

    Covered when ALL of the following are met

    Step 2 coverage criteria for RYTARY products: Prior use of carbidopa-levodopa immediate-release or extended-release tablets within the previous 12 months.12 months

    Applies to the listed carbidopa-levodopa ER capsule strengths (23.75/95 mg, 36.25/145 mg, 48.75/195 mg, 61.25/245 mg).

    Tazarotene topical Initial Step Requirement

    Covered when ALL of the following are met

    Step 2 coverage criteria for tazarotene topical products: Prior use of tazarotene 0.1% cream within the previous 12 months.12 months

    Applies to tazarotene 0.05% cream, 0.05% gel, and 0.1% gel listed as Step 2.

    The policy text does not list any explicit clinical exclusions or contraindications for the Step 2 products. No conditions or patient clinical factors are specified in the document as reasons to exclude coverage beyond the stated prior-use requirements.

    The document does not specify particular "not medically necessary" scenarios. Coverage determinations are governed by the Step Therapy rules: failure to meet the prior-use requirement described in the policy (see product-specific criteria) means the Step 2 product would not meet the stated coverage criteria.

    Coding and Lookback

    RYTARY / Carbidopa-levodopa ER products (Step 2)NDC|mixed
    CARBIDOPA ER 23.75 MG-LEVODOPA 95 MGCAPSULE, EXTENDED RELEASE
    CARBIDOPA ER 36.25 MG-LEVODOPA 145 MGCAPSULE, EXTENDED RELEASE
    CARBIDOPA ER 48.75 MG-LEVODOPA 195 MGCAPSULE, EXTENDED RELEASE
    CARBIDOPA ER 61.25 MG-LEVODOPA 245 MGCAPSULE, EXTENDED RELEASE
    Tazarotene topical products (Step 2)NDC|mixed
    tazarotene 0.05% topical creamproduct affected Step 2
    tazarotene 0.05% topical gelproduct affected Step 2
    tazarotene 0.1% topical gelproduct affected Step 2
    Prior-use lookback period
    Prior-use lookback period12 months
    Lookback phrasing in policywithin the previous 12 months
    Applies to Step 2 products listed on Formulary FID: 26132Effective 05/01/2026

    Provider Actions and Documentation Requirements

    Step Therapy

    Medicare Part D prior-use requirement for Step Therapy

    For Medicare Part D claims, Step 2 coverage on HealthPartners’ Part D formulary (FID: 26132) requires documented prior use of the specified comparator product within the previous 12 months before the listed Step 2 products will be covered.

    • Formulary identifier: FID: 26132
    • Lookback period: within the previous 12 months
    Step Therapy

    Step 2 requires prior use of specified comparator within 12 months

    Coverage of the listed Step 2 products (RYTARY and tazarotene topical products) is contingent on prior use of the specified lower-step or comparator product within the previous 12 months; without this prior use the Step 2 product does not meet the step-therapy requirement.

    • Applies to RYTARY (listed carbidopa‑levodopa ER capsule strengths) and the listed tazarotene topical products
    • Required lookback: 12 months
    Documentation Required

    Provide documentation of prior use within 12 months

    Documented evidence must explicitly show prior use of the specified comparator (e.g., carbidopa‑levodopa immediate‑release or extended‑release tablets for RYTARY; tazarotene 0.1% cream for tazarotene Step 2 products) within the previous 12 months to satisfy the step‑therapy criterion.

    • Evidence may include prior prescription fills or medical record notation demonstrating use within the previous 12 months
    • Comparator examples: carbidopa‑levodopa immediate‑release or extended‑release tablets; tazarotene 0.1% cream
    Denial Risk

    Lack of documented prior use may lead to denial

    If there is no documentation showing prior use of the specified comparator product within the previous 12 months, coverage for the Step 2 product may be denied.

    • Absence of prior‑use documentation is a basis for denial of coverage for the Step 2 products listed

    Initial Therapy / Step 2 Prerequisites

    Initial Therapy / Step 2 prerequisites

    Prior documented use within the specified lookback period is required for coverage of Step 2 products listed below.

    Step 2 prior-use prerequisite: Prior use of the specified comparator product within the previous 12 months is required before coverage of the listed Step 2 products.

    Step Therapy Table

    RequirementLookback periodCoverage implication
    Prior documented use of the specified comparator product (e.g., carbidopa-levodopa immediate‑release or extended‑release tablets for RYTARY; tazarotene 0.1% cream for tazarotene topical products) is required before covering the Step 2 product.
    12 months (use within the previous 12 months)
    Coverage granted only if documentation shows prior use within the 12‑month lookback; absence of prior use may result in denial of coverage for the Step 2 product.

    Definitions

    Prior use (definition)
    Definition of prior useUse of the specified comparator product (e.g., carbidopa-levodopa immediate‑release or extended‑release tablets; or tazarotene 0.1% cream) within the previous 12 months
    Evidence requiredDocumentation must demonstrate prior use within the 12‑month lookback to meet Step 2 criteria
    Consequences of absenceAbsence of documented prior use within 12 months may result in denial of coverage for the Step 2 product

    Background

    This policy lists Medicare Part D step therapy prior-use requirements for specific Part D formulary medications. For the products affected, coverage as a Step 2 product requires documented prior use of the specified comparator within a 12-month lookback period.

    Policy Summary
    PayerHealthPartners
    Policy2026 Medicare Part D Step Therapy Requirements
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Last ReviewApr 21, 2026
    Next Review DateApril 21, 2026
    Key ActionDocument prior use of the specified comparator product within the previous 12 months to satisfy step therapy requirements for listed Step 2 drugs.
    SourceLink
    On This Page
    Coverage CriteriaCoding and LookbackProvider Actions and Documentation RequirementsInitial Therapy / Step 2 PrerequisitesStep Therapy TableDefinitionsBackground